author-photo

Hongmei Li

Takeda Pharmaceutical Company

3

Papers

45

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.

2017 Journal of Hematology & Oncology
Show All
- Source
- Cite
- Save
Citations (38)
Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1

2017 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)